Drug intelligence / Profile preview

CPB2205

Development stage: Preclinical
Lead developer: Corepharm Bio

Overview

**CPB2205** is a Corepharm Bio development program listed in the company pipeline under **NSAIDs**. Publicly available pipeline information does not disclose its chemical identity, specific molecular target, mechanism of action, formulation, route of administration, or development phase. It is therefore best characterized as an undisclosed anti-inflammatory or analgesic pharmaceutical candidate rather than assigned to a specific NSAID subclass. ([corepharm.com](https://www.corepharm.com/eng/product/pipeline.php))

Targets

COX

Beyond the preview

Go deeper on CPB2205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPB2205.

Explore the full profile